| 60.1255 1.386 (2.36%) | 09-11 12:11 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 73.73  |
1-year : | 85.21 |
| Resists | First : | 63.12 |
Second : | 72.95 |
| Pivot price | 64.73 |
|||
| Supports | First : | 47.22 |
Second : | 39.29 |
| MAs | MA(5) : | 61.66 |
MA(20) : | 62.6 |
| MA(100) : | 53.22 |
MA(250) : | 61.74 |
|
| MACD | MACD : | 1.8 |
Signal : | 2.9 |
| %K %D | K(14,3) : | 16.5 |
D(3) : | 35.2 |
| RSI | RSI(14): 48.9 |
|||
| 52-week | High : | 104.31 | Low : | 40.77 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TEM ] has closed above bottom band by 15.5%. Bollinger Bands are 3.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 61.19 - 61.62 | 61.62 - 61.95 |
| Low: | 56.93 - 57.5 | 57.5 - 57.93 |
| Close: | 57.96 - 58.72 | 58.72 - 59.31 |
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Fri, 11 Sep 2026
Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation - Finviz
Fri, 11 Sep 2026
Tempus AI plans 100,000 whole genome sequencing dataset - Investing.com
Fri, 11 Sep 2026
Tempus AI (NASDAQ:TEM) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Fri, 11 Sep 2026
TEM Maintained by HC Wainwright & Co. -- Price Target Raised to $66.00 - GuruFocus
Fri, 11 Sep 2026
H.C. Wainwright raises Tempus AI stock price target to $66 - Investing.com
Thu, 10 Sep 2026
Tempus AI, Inc. • Robinhood Token (TEM) Price Prediction for 2026 to 2031 - Bybit
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 175 (M) |
| Held by Insiders | 1.159e+008 (%) |
| Held by Institutions | 36.7 (%) |
| Shares Short | 30,360 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.9336e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -17.8 % |
| Return on Assets (ttm) | -20.2 % |
| Return on Equity (ttm) | -8.6 % |
| Qtrly Rev. Growth | 1.43e+009 % |
| Gross Profit (p.s.) | 5.8 |
| Sales Per Share | -18.13 |
| EBITDA (p.s.) | 2.46288e+008 |
| Qtrly Earnings Growth | -1.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -237 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 689.1 |
| Price to Book value | 0 |
| Price to Sales | -3.28 |
| Price to Cash Flow | 89.46 |
| Dividend | 0 |
| Forward Dividend | 2.987e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|